ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1ISRG | INTUITIVE SURGICAL INC | Healthcare | $152.49B | 30.59% |
2DXCM | DEXCOM INC | Healthcare | $30.35B | 6.09% |
3ROIV | ROIVANT SCIENCES LTD | Healthcare | $28.98B | 5.81% |
4INSM | INSMED INC | Healthcare | $25.90B | 5.20% |
5UTHR | UNITED THERAPEUTICS CORP | Healthcare | $25.27B | 5.07% |
6VTRS | VIATRIS INC | Healthcare | $23.70B | 4.75% |
7NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.15B | 3.44% |
8JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.43B | 3.10% |
9BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $14.22B | 2.85% |
10PCVX | VAXCYTE INC | Healthcare | $10.24B | 2.05% |
11OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 1.99% |
12MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $9.88B | 1.98% |
13HNGE | HINGE HEALTH INC | Healthcare | $9.83B | 1.97% |
14RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.62B | 1.53% |
15KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 1.36% |
16LNTH | LANTHEUS HOLDINGS INC | Healthcare | $6.62B | 1.33% |
17TFX | TELEFLEX INC | Healthcare | $6.07B | 1.22% |
18DOCS | DOXIMITY INC | Healthcare | $5.92B | 1.19% |
19SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $5.27B | 1.06% |
20LQDA | LIQUIDIA CORP | Healthcare | $5.24B | 1.05% |
21IONS | IONIS PHARMACEUTICALS INC | Healthcare | $4.55B | 0.91% |
22CDNA | CAREDX INC | Healthcare | $4.19B | 0.84% |
23TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $3.79B | 0.76% |
24VKTX | VIKING THERAPEUTICS INC | Healthcare | $3.52B | 0.71% |
25WRBY | WARBY PARKER INC | Healthcare | $3.32B | 0.67% |
26IRTC | IRHYTHM HOLDINGS INC | Healthcare | $3.15B | 0.63% |
27DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.03B | 0.61% |
28XNCR | XENCOR INC | Healthcare | $2.86B | 0.57% |
29PGNY | PROGYNY INC | Healthcare | $2.69B | 0.54% |
30RCUS | ARCUS BIOSCIENCES INC | Healthcare | $2.56B | 0.51% |
31SDGR | SCHRODINGER INC | Healthcare | $2.32B | 0.46% |
32PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.45% |
33VERA | VERA THERAPEUTICS INC | Healthcare | $2.10B | 0.42% |
34REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.42% |
35VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 0.42% |
36FTRE | FORTREA HOLDINGS INC | Healthcare | $1.94B | 0.39% |
37AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $1.90B | 0.38% |
38RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $1.66B | 0.33% |
39ENOV | ENOVIS CORP | Healthcare | $1.59B | 0.32% |
40TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.32% |
41ABSI | ABSCI CORP | Healthcare | $1.57B | 0.31% |
42PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.29% |
43NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.29% |
44AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.29% |
45ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.29% |
46KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.29% |
47NVCR | NOVOCURE LTD | Healthcare | $1.37B | 0.27% |
48CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.29B | 0.26% |
49INNV | INNOVAGE HOLDING CORP | Healthcare | $1.28B | 0.26% |
50AHCO | ADAPTHEALTH CORP | Healthcare | $1.07B | 0.22% |
51VSTM | VERASTEM INC | Healthcare | $1.06B | 0.21% |
52CBLL | CERIBELL INC | Healthcare | $1.02B | 0.21% |
53FLGT | FULGENT GENETICS INC | Healthcare | $694M | 0.14% |
54KURA | KURA ONCOLOGY INC | Healthcare | $683M | 0.14% |
55ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $664M | 0.13% |
56DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.13% |
57CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $662M | 0.13% |
58SRZN | SURROZEN INC | Healthcare | $604M | 0.12% |
59MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.11% |
60RGNX | REGENXBIO INC | Healthcare | $531M | 0.11% |
61TKNO | ALPHA TEKNOVA INC | Healthcare | $522M | 0.10% |
62SRTA | STRATA CRITICAL MEDICAL INC | Healthcare | $515M | 0.10% |
63RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.10% |
64PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.10% |
65ANGO | ANGIODYNAMICS INC | Healthcare | $504M | 0.10% |
66DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $503M | 0.10% |
67CTEV | CLARITEV CORP | Healthcare | $459M | 0.09% |
68ARVN | ARVINAS INC | Healthcare | $450M | 0.09% |
69SI | SHOULDER INNOVATIONS INC | Healthcare | $441M | 0.09% |
70LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.08% |
71TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.07% |
72VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.07% |
73EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.06% |
74RXST | RXSIGHT INC | Healthcare | $226M | 0.05% |
75GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.05% |
76PDEX | PRO DEX INC | Healthcare | $216M | 0.04% |
77AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.04% |
78TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.04% |
79CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.03% |
80SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $123M | 0.02% |
81RLYB | RALLYBIO CORP | Healthcare | $84M | 0.02% |
82ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.02% |
83GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.01% |
84COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.01% |
85YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $498.43B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 92% toward Large, 79% toward Growth. +9% unclassified (17 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 85 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 85 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 69.2% | 61.0% |
| 3 yearsp.a. | 30.2% | 5.5% |
| 5 yearsp.a. | 11.0% | 4.8% |
| 10 yearsp.a. | 14.9% | 4.3% |
| Since inceptionp.a. | 13.3% | 5.7% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 68.8% | 59.3% |
| 2025 | 23.4% | -13.0% |
| 2024 | -1.3% | -9.1% |
| 2023 | 3.1% | -1.5% |
| 2022 | -18.2% | 6.5% |
| 2021 | 18.3% | 26.2% |
| 2020 | 9.6% | -28.7% |
| 2019 | 17.8% | -7.2% |
| 2018 | 6.7% | 18.0% |
| 2017 | 43.0% | 12.2% |
| 2016 | -8.4% | 8.6% |
| 2015 | 8.4% | -9.2% |
| 2014 | 27.7% | 3.4% |
| 2013 | 52.8% | 4.6% |
| 2012 | 21.1% | 9.3% |
| 2011 | 13.2% | 4.7% |
| 2010 | 18.4% | 13.7% |
| 2009 | 17.8% | 0.7% |
| 2008 | -19.9% | 14.4% |
| 2007 | 3.3% | -20.1% |
| 2006 | 18.1% | 11.7% |
| 2005 | 4.6% | 1.3% |
| 2004 | -12.0% | -15.5% |
| 2003 | 82.5% | 48.2% |
| 2002 | -35.1% | 3.7% |
| 2001 | -4.2% | 33.9% |
| 2000 | 30.8% | -14.9% |
| 1999 | 61.9% | 51.9% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Earnings Quality (Accruals) Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Earnings Quality (Accruals) signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.